nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—ABCB1—ovarian cancer	0.26	1	CbGaD
Dipyridamole—PDE5A—clitoris—ovarian cancer	0.0308	0.13	CbGeAlD
Dipyridamole—PRUNE—uterine cervix—ovarian cancer	0.00451	0.0191	CbGeAlD
Dipyridamole—PDE6D—uterine cervix—ovarian cancer	0.00436	0.0184	CbGeAlD
Dipyridamole—PDE6A—testis—ovarian cancer	0.00431	0.0182	CbGeAlD
Dipyridamole—PRUNE—Vincristine—Vinorelbine—ovarian cancer	0.00424	0.554	CbGdCrCtD
Dipyridamole—PDE6D—decidua—ovarian cancer	0.00415	0.0175	CbGeAlD
Dipyridamole—PDE11A—epithelium—ovarian cancer	0.00402	0.017	CbGeAlD
Dipyridamole—PRUNE—uterus—ovarian cancer	0.00376	0.0159	CbGeAlD
Dipyridamole—PDE6D—uterus—ovarian cancer	0.00363	0.0153	CbGeAlD
Dipyridamole—PRUNE—Vinblastine—Vinorelbine—ovarian cancer	0.00341	0.446	CbGdCrCtD
Dipyridamole—PDE2A—myometrium—ovarian cancer	0.00333	0.0141	CbGeAlD
Dipyridamole—PDE6D—female reproductive system—ovarian cancer	0.00327	0.0138	CbGeAlD
Dipyridamole—PDE6D—bone marrow—ovarian cancer	0.00308	0.013	CbGeAlD
Dipyridamole—PRUNE—female gonad—ovarian cancer	0.00308	0.013	CbGeAlD
Dipyridamole—PDE1C—testis—ovarian cancer	0.00303	0.0128	CbGeAlD
Dipyridamole—PDE6D—female gonad—ovarian cancer	0.00297	0.0125	CbGeAlD
Dipyridamole—PDE6D—vagina—ovarian cancer	0.00295	0.0125	CbGeAlD
Dipyridamole—PDE6B—vagina—ovarian cancer	0.00291	0.0123	CbGeAlD
Dipyridamole—PDE8A—myometrium—ovarian cancer	0.00286	0.0121	CbGeAlD
Dipyridamole—PRUNE—testis—ovarian cancer	0.00273	0.0115	CbGeAlD
Dipyridamole—PDE7A—female reproductive system—ovarian cancer	0.00266	0.0112	CbGeAlD
Dipyridamole—PDE6D—testis—ovarian cancer	0.00264	0.0111	CbGeAlD
Dipyridamole—PDE6B—testis—ovarian cancer	0.00259	0.0109	CbGeAlD
Dipyridamole—PDE2A—uterine cervix—ovarian cancer	0.00259	0.0109	CbGeAlD
Dipyridamole—PDE8B—uterine cervix—ovarian cancer	0.00247	0.0104	CbGeAlD
Dipyridamole—PDE10A—decidua—ovarian cancer	0.00247	0.0104	CbGeAlD
Dipyridamole—PDE2A—decidua—ovarian cancer	0.00247	0.0104	CbGeAlD
Dipyridamole—PDE11A—testis—ovarian cancer	0.00241	0.0102	CbGeAlD
Dipyridamole—ADA—myometrium—ovarian cancer	0.00235	0.00993	CbGeAlD
Dipyridamole—PDE6G—testis—ovarian cancer	0.00232	0.0098	CbGeAlD
Dipyridamole—PDE8A—uterine cervix—ovarian cancer	0.00222	0.00939	CbGeAlD
Dipyridamole—PDE1C—lymph node—ovarian cancer	0.00219	0.00926	CbGeAlD
Dipyridamole—PDE2A—uterus—ovarian cancer	0.00216	0.00912	CbGeAlD
Dipyridamole—PDE1B—gonad—ovarian cancer	0.00215	0.0091	CbGeAlD
Dipyridamole—PDE1A—uterine cervix—ovarian cancer	0.00215	0.00909	CbGeAlD
Dipyridamole—PDE8A—decidua—ovarian cancer	0.00212	0.00895	CbGeAlD
Dipyridamole—PDE8B—gonad—ovarian cancer	0.00207	0.00876	CbGeAlD
Dipyridamole—PDE8B—uterus—ovarian cancer	0.00206	0.0087	CbGeAlD
Dipyridamole—PDE8A—endometrium—ovarian cancer	0.00201	0.00849	CbGeAlD
Dipyridamole—PRUNE—lymph node—ovarian cancer	0.00198	0.00835	CbGeAlD
Dipyridamole—PDE2A—female reproductive system—ovarian cancer	0.00194	0.0082	CbGeAlD
Dipyridamole—PDE1B—female reproductive system—ovarian cancer	0.00192	0.00813	CbGeAlD
Dipyridamole—PDE6D—lymph node—ovarian cancer	0.00191	0.00807	CbGeAlD
Dipyridamole—PDE7B—testis—ovarian cancer	0.00188	0.00793	CbGeAlD
Dipyridamole—PDE8A—uterus—ovarian cancer	0.00185	0.00783	CbGeAlD
Dipyridamole—PDE8B—female reproductive system—ovarian cancer	0.00185	0.00782	CbGeAlD
Dipyridamole—PDE1A—gonad—ovarian cancer	0.00181	0.00763	CbGeAlD
Dipyridamole—PDE1A—uterus—ovarian cancer	0.00179	0.00758	CbGeAlD
Dipyridamole—PDE10A—female gonad—ovarian cancer	0.00177	0.00746	CbGeAlD
Dipyridamole—PDE2A—vagina—ovarian cancer	0.00176	0.00742	CbGeAlD
Dipyridamole—ADA—decidua—ovarian cancer	0.00174	0.00736	CbGeAlD
Dipyridamole—PDE3B—bone marrow—ovarian cancer	0.00171	0.00721	CbGeAlD
Dipyridamole—PDE4A—decidua—ovarian cancer	0.0017	0.00718	CbGeAlD
Dipyridamole—PDE6G—lymph node—ovarian cancer	0.00168	0.0071	CbGeAlD
Dipyridamole—PDE8B—vagina—ovarian cancer	0.00168	0.00708	CbGeAlD
Dipyridamole—SLC29A1—myometrium—ovarian cancer	0.00164	0.00691	CbGeAlD
Dipyridamole—PDE1A—female reproductive system—ovarian cancer	0.00161	0.00681	CbGeAlD
Dipyridamole—PDE10A—testis—ovarian cancer	0.00157	0.00662	CbGeAlD
Dipyridamole—PDE2A—testis—ovarian cancer	0.00157	0.00662	CbGeAlD
Dipyridamole—PDE1B—testis—ovarian cancer	0.00155	0.00656	CbGeAlD
Dipyridamole—PDE5A—epithelium—ovarian cancer	0.00153	0.00646	CbGeAlD
Dipyridamole—PDE5A—uterine cervix—ovarian cancer	0.00152	0.0064	CbGeAlD
Dipyridamole—PDE8A—female gonad—ovarian cancer	0.00152	0.0064	CbGeAlD
Dipyridamole—PDE8A—vagina—ovarian cancer	0.00151	0.00636	CbGeAlD
Dipyridamole—PDE8B—testis—ovarian cancer	0.0015	0.00631	CbGeAlD
Dipyridamole—PDE1A—female gonad—ovarian cancer	0.00147	0.0062	CbGeAlD
Dipyridamole—PDE3B—testis—ovarian cancer	0.00146	0.00617	CbGeAlD
Dipyridamole—ABCC5—uterine cervix—ovarian cancer	0.00139	0.00586	CbGeAlD
Dipyridamole—ADA—female reproductive system—ovarian cancer	0.00137	0.00579	CbGeAlD
Dipyridamole—PDE7B—lymph node—ovarian cancer	0.00136	0.00575	CbGeAlD
Dipyridamole—PDE8A—testis—ovarian cancer	0.00134	0.00568	CbGeAlD
Dipyridamole—ABCC5—decidua—ovarian cancer	0.00132	0.00558	CbGeAlD
Dipyridamole—PDE1A—testis—ovarian cancer	0.0013	0.0055	CbGeAlD
Dipyridamole—ADA—bone marrow—ovarian cancer	0.00129	0.00547	CbGeAlD
Dipyridamole—SLC29A1—uterine cervix—ovarian cancer	0.00127	0.00538	CbGeAlD
Dipyridamole—PDE5A—gonad—ovarian cancer	0.00127	0.00537	CbGeAlD
Dipyridamole—ADA—vagina—ovarian cancer	0.00124	0.00524	CbGeAlD
Dipyridamole—PDE4A—female gonad—ovarian cancer	0.00122	0.00513	CbGeAlD
Dipyridamole—SLC29A1—decidua—ovarian cancer	0.00121	0.00512	CbGeAlD
Dipyridamole—SLC29A1—endometrium—ovarian cancer	0.00115	0.00486	CbGeAlD
Dipyridamole—PDE5A—female reproductive system—ovarian cancer	0.00114	0.0048	CbGeAlD
Dipyridamole—PDE2A—lymph node—ovarian cancer	0.00114	0.0048	CbGeAlD
Dipyridamole—PDE10A—lymph node—ovarian cancer	0.00114	0.0048	CbGeAlD
Dipyridamole—PDE1B—lymph node—ovarian cancer	0.00113	0.00475	CbGeAlD
Dipyridamole—ADA—testis—ovarian cancer	0.00111	0.00467	CbGeAlD
Dipyridamole—PDE3A—female reproductive system—ovarian cancer	0.00111	0.00467	CbGeAlD
Dipyridamole—PDE8B—lymph node—ovarian cancer	0.00108	0.00458	CbGeAlD
Dipyridamole—PDE4A—testis—ovarian cancer	0.00108	0.00455	CbGeAlD
Dipyridamole—SLC29A1—gonad—ovarian cancer	0.00107	0.00451	CbGeAlD
Dipyridamole—SLC29A1—uterus—ovarian cancer	0.00106	0.00448	CbGeAlD
Dipyridamole—PDE3B—lymph node—ovarian cancer	0.00106	0.00447	CbGeAlD
Dipyridamole—PDE5A—female gonad—ovarian cancer	0.00103	0.00437	CbGeAlD
Dipyridamole—PDE5A—vagina—ovarian cancer	0.00103	0.00434	CbGeAlD
Dipyridamole—PDE3A—female gonad—ovarian cancer	0.00101	0.00425	CbGeAlD
Dipyridamole—ABCC5—bone marrow—ovarian cancer	0.000981	0.00414	CbGeAlD
Dipyridamole—PDE8A—lymph node—ovarian cancer	0.000975	0.00412	CbGeAlD
Dipyridamole—SLC29A1—female reproductive system—ovarian cancer	0.000954	0.00403	CbGeAlD
Dipyridamole—ABCC5—female gonad—ovarian cancer	0.000946	0.00399	CbGeAlD
Dipyridamole—PDE1A—lymph node—ovarian cancer	0.000943	0.00398	CbGeAlD
Dipyridamole—ABCC5—vagina—ovarian cancer	0.00094	0.00397	CbGeAlD
Dipyridamole—PDE5A—testis—ovarian cancer	0.000917	0.00387	CbGeAlD
Dipyridamole—SLC29A1—bone marrow—ovarian cancer	0.000901	0.0038	CbGeAlD
Dipyridamole—PDE3A—testis—ovarian cancer	0.000892	0.00377	CbGeAlD
Dipyridamole—SLC29A1—female gonad—ovarian cancer	0.000868	0.00367	CbGeAlD
Dipyridamole—SLC29A1—vagina—ovarian cancer	0.000863	0.00364	CbGeAlD
Dipyridamole—ABCC5—testis—ovarian cancer	0.000839	0.00354	CbGeAlD
Dipyridamole—ADA—lymph node—ovarian cancer	0.000802	0.00339	CbGeAlD
Dipyridamole—ABCC4—uterus—ovarian cancer	0.000801	0.00338	CbGeAlD
Dipyridamole—PDE4A—lymph node—ovarian cancer	0.000782	0.0033	CbGeAlD
Dipyridamole—SLC29A1—testis—ovarian cancer	0.00077	0.00325	CbGeAlD
Dipyridamole—ABCC4—female reproductive system—ovarian cancer	0.00072	0.00304	CbGeAlD
Dipyridamole—ABCC4—bone marrow—ovarian cancer	0.00068	0.00287	CbGeAlD
Dipyridamole—PDE5A—lymph node—ovarian cancer	0.000665	0.00281	CbGeAlD
Dipyridamole—ABCC4—female gonad—ovarian cancer	0.000655	0.00277	CbGeAlD
Dipyridamole—PDE3A—lymph node—ovarian cancer	0.000647	0.00273	CbGeAlD
Dipyridamole—ABCC5—lymph node—ovarian cancer	0.000608	0.00257	CbGeAlD
Dipyridamole—ABCC4—testis—ovarian cancer	0.000581	0.00245	CbGeAlD
Dipyridamole—SLC29A1—lymph node—ovarian cancer	0.000558	0.00236	CbGeAlD
Dipyridamole—ABCB1—myometrium—ovarian cancer	0.00043	0.00182	CbGeAlD
Dipyridamole—ABCC4—lymph node—ovarian cancer	0.000421	0.00178	CbGeAlD
Dipyridamole—ABCB1—embryo—ovarian cancer	0.000414	0.00175	CbGeAlD
Dipyridamole—ABCB1—epithelium—ovarian cancer	0.000338	0.00143	CbGeAlD
Dipyridamole—ABCB1—uterine cervix—ovarian cancer	0.000335	0.00141	CbGeAlD
Dipyridamole—ABCB1—decidua—ovarian cancer	0.000319	0.00135	CbGeAlD
Dipyridamole—Dermatitis—Melphalan—ovarian cancer	0.000318	0.0013	CcSEcCtD
Dipyridamole—Chills—Docetaxel—ovarian cancer	0.000318	0.0013	CcSEcCtD
Dipyridamole—Cough—Paclitaxel—ovarian cancer	0.000318	0.0013	CcSEcCtD
Dipyridamole—Asthenia—Vinorelbine—ovarian cancer	0.000317	0.00129	CcSEcCtD
Dipyridamole—Arrhythmia—Docetaxel—ovarian cancer	0.000317	0.00129	CcSEcCtD
Dipyridamole—Abdominal pain upper—Epirubicin—ovarian cancer	0.000316	0.00129	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000316	0.00129	CcSEcCtD
Dipyridamole—Convulsion—Paclitaxel—ovarian cancer	0.000315	0.00129	CcSEcCtD
Dipyridamole—Migraine—Doxorubicin—ovarian cancer	0.000315	0.00128	CcSEcCtD
Dipyridamole—Hypertension—Paclitaxel—ovarian cancer	0.000314	0.00128	CcSEcCtD
Dipyridamole—Alopecia—Docetaxel—ovarian cancer	0.000313	0.00128	CcSEcCtD
Dipyridamole—Pruritus—Vinorelbine—ovarian cancer	0.000312	0.00128	CcSEcCtD
Dipyridamole—Myalgia—Paclitaxel—ovarian cancer	0.00031	0.00127	CcSEcCtD
Dipyridamole—Arthralgia—Paclitaxel—ovarian cancer	0.00031	0.00127	CcSEcCtD
Dipyridamole—Chest pain—Paclitaxel—ovarian cancer	0.00031	0.00127	CcSEcCtD
Dipyridamole—Anxiety—Paclitaxel—ovarian cancer	0.000309	0.00126	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000308	0.00126	CcSEcCtD
Dipyridamole—Nausea—Topotecan—ovarian cancer	0.000307	0.00125	CcSEcCtD
Dipyridamole—Discomfort—Paclitaxel—ovarian cancer	0.000306	0.00125	CcSEcCtD
Dipyridamole—Cardiac arrest—Doxorubicin—ovarian cancer	0.000304	0.00124	CcSEcCtD
Dipyridamole—Dry mouth—Paclitaxel—ovarian cancer	0.000303	0.00124	CcSEcCtD
Dipyridamole—ABCB1—endometrium—ovarian cancer	0.000303	0.00128	CbGeAlD
Dipyridamole—Diarrhoea—Vinorelbine—ovarian cancer	0.000302	0.00123	CcSEcCtD
Dipyridamole—Dysgeusia—Docetaxel—ovarian cancer	0.000302	0.00123	CcSEcCtD
Dipyridamole—Nausea—Melphalan—ovarian cancer	0.0003	0.00123	CcSEcCtD
Dipyridamole—Dysphagia—Epirubicin—ovarian cancer	0.000299	0.00122	CcSEcCtD
Dipyridamole—Back pain—Docetaxel—ovarian cancer	0.000298	0.00122	CcSEcCtD
Dipyridamole—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000297	0.00121	CcSEcCtD
Dipyridamole—Oedema—Paclitaxel—ovarian cancer	0.000297	0.00121	CcSEcCtD
Dipyridamole—Muscle spasms—Docetaxel—ovarian cancer	0.000297	0.00121	CcSEcCtD
Dipyridamole—Shock—Paclitaxel—ovarian cancer	0.000292	0.00119	CcSEcCtD
Dipyridamole—Dizziness—Vinorelbine—ovarian cancer	0.000292	0.00119	CcSEcCtD
Dipyridamole—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000292	0.00119	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000292	0.00119	CcSEcCtD
Dipyridamole—Nervous system disorder—Paclitaxel—ovarian cancer	0.000291	0.00119	CcSEcCtD
Dipyridamole—Angina pectoris—Epirubicin—ovarian cancer	0.000291	0.00119	CcSEcCtD
Dipyridamole—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000291	0.00119	CcSEcCtD
Dipyridamole—Tachycardia—Paclitaxel—ovarian cancer	0.00029	0.00118	CcSEcCtD
Dipyridamole—Skin disorder—Paclitaxel—ovarian cancer	0.000288	0.00118	CcSEcCtD
Dipyridamole—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000287	0.00117	CcSEcCtD
Dipyridamole—Anaemia—Docetaxel—ovarian cancer	0.000285	0.00116	CcSEcCtD
Dipyridamole—ABCB1—gonad—ovarian cancer	0.000281	0.00119	CbGeAlD
Dipyridamole—Vomiting—Vinorelbine—ovarian cancer	0.000281	0.00115	CcSEcCtD
Dipyridamole—ABCB1—uterus—ovarian cancer	0.000279	0.00118	CbGeAlD
Dipyridamole—Rash—Vinorelbine—ovarian cancer	0.000278	0.00114	CcSEcCtD
Dipyridamole—Dermatitis—Vinorelbine—ovarian cancer	0.000278	0.00114	CcSEcCtD
Dipyridamole—Hypotension—Paclitaxel—ovarian cancer	0.000278	0.00113	CcSEcCtD
Dipyridamole—Headache—Vinorelbine—ovarian cancer	0.000277	0.00113	CcSEcCtD
Dipyridamole—Syncope—Docetaxel—ovarian cancer	0.000277	0.00113	CcSEcCtD
Dipyridamole—Dysphagia—Doxorubicin—ovarian cancer	0.000276	0.00113	CcSEcCtD
Dipyridamole—Palpitations—Docetaxel—ovarian cancer	0.000273	0.00111	CcSEcCtD
Dipyridamole—Loss of consciousness—Docetaxel—ovarian cancer	0.000271	0.00111	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000271	0.00111	CcSEcCtD
Dipyridamole—Cough—Docetaxel—ovarian cancer	0.000269	0.0011	CcSEcCtD
Dipyridamole—Angina pectoris—Doxorubicin—ovarian cancer	0.000269	0.0011	CcSEcCtD
Dipyridamole—Convulsion—Docetaxel—ovarian cancer	0.000267	0.00109	CcSEcCtD
Dipyridamole—Paraesthesia—Paclitaxel—ovarian cancer	0.000267	0.00109	CcSEcCtD
Dipyridamole—Hypertension—Docetaxel—ovarian cancer	0.000266	0.00109	CcSEcCtD
Dipyridamole—Dyspnoea—Paclitaxel—ovarian cancer	0.000265	0.00108	CcSEcCtD
Dipyridamole—Somnolence—Paclitaxel—ovarian cancer	0.000264	0.00108	CcSEcCtD
Dipyridamole—Chest pain—Docetaxel—ovarian cancer	0.000263	0.00107	CcSEcCtD
Dipyridamole—Arthralgia—Docetaxel—ovarian cancer	0.000263	0.00107	CcSEcCtD
Dipyridamole—Myalgia—Docetaxel—ovarian cancer	0.000263	0.00107	CcSEcCtD
Dipyridamole—Nausea—Vinorelbine—ovarian cancer	0.000262	0.00107	CcSEcCtD
Dipyridamole—Dyspepsia—Paclitaxel—ovarian cancer	0.000261	0.00107	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000261	0.00107	CcSEcCtD
Dipyridamole—Dry mouth—Docetaxel—ovarian cancer	0.000257	0.00105	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000256	0.00105	CcSEcCtD
Dipyridamole—Fatigue—Paclitaxel—ovarian cancer	0.000256	0.00105	CcSEcCtD
Dipyridamole—Pain—Paclitaxel—ovarian cancer	0.000254	0.00104	CcSEcCtD
Dipyridamole—Anaphylactic shock—Docetaxel—ovarian cancer	0.000252	0.00103	CcSEcCtD
Dipyridamole—Oedema—Docetaxel—ovarian cancer	0.000252	0.00103	CcSEcCtD
Dipyridamole—ABCB1—female reproductive system—ovarian cancer	0.000251	0.00106	CbGeAlD
Dipyridamole—Shock—Docetaxel—ovarian cancer	0.000248	0.00101	CcSEcCtD
Dipyridamole—Nervous system disorder—Docetaxel—ovarian cancer	0.000247	0.00101	CcSEcCtD
Dipyridamole—Thrombocytopenia—Docetaxel—ovarian cancer	0.000246	0.00101	CcSEcCtD
Dipyridamole—Tachycardia—Docetaxel—ovarian cancer	0.000246	0.001	CcSEcCtD
Dipyridamole—Feeling abnormal—Paclitaxel—ovarian cancer	0.000245	0.001	CcSEcCtD
Dipyridamole—Skin disorder—Docetaxel—ovarian cancer	0.000245	0.000999	CcSEcCtD
Dipyridamole—Bradycardia—Epirubicin—ovarian cancer	0.000243	0.000994	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000243	0.000992	CcSEcCtD
Dipyridamole—Haemoglobin—Epirubicin—ovarian cancer	0.00024	0.000981	CcSEcCtD
Dipyridamole—Rhinitis—Epirubicin—ovarian cancer	0.00024	0.000979	CcSEcCtD
Dipyridamole—Haemorrhage—Epirubicin—ovarian cancer	0.000239	0.000976	CcSEcCtD
Dipyridamole—Hepatitis—Epirubicin—ovarian cancer	0.000239	0.000976	CcSEcCtD
Dipyridamole—Hypoaesthesia—Epirubicin—ovarian cancer	0.000238	0.000971	CcSEcCtD
Dipyridamole—Pharyngitis—Epirubicin—ovarian cancer	0.000237	0.000969	CcSEcCtD
Dipyridamole—ABCB1—bone marrow—ovarian cancer	0.000237	0.001	CbGeAlD
Dipyridamole—Urticaria—Paclitaxel—ovarian cancer	0.000236	0.000964	CcSEcCtD
Dipyridamole—Hypotension—Docetaxel—ovarian cancer	0.000235	0.000961	CcSEcCtD
Dipyridamole—Abdominal pain—Paclitaxel—ovarian cancer	0.000235	0.000959	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000229	0.000937	CcSEcCtD
Dipyridamole—ABCB1—female gonad—ovarian cancer	0.000228	0.000964	CbGeAlD
Dipyridamole—ABCB1—vagina—ovarian cancer	0.000227	0.000958	CbGeAlD
Dipyridamole—Paraesthesia—Docetaxel—ovarian cancer	0.000226	0.000923	CcSEcCtD
Dipyridamole—Bradycardia—Doxorubicin—ovarian cancer	0.000225	0.000919	CcSEcCtD
Dipyridamole—Dyspnoea—Docetaxel—ovarian cancer	0.000224	0.000917	CcSEcCtD
Dipyridamole—Somnolence—Docetaxel—ovarian cancer	0.000224	0.000914	CcSEcCtD
Dipyridamole—Tinnitus—Epirubicin—ovarian cancer	0.000223	0.00091	CcSEcCtD
Dipyridamole—Haemoglobin—Doxorubicin—ovarian cancer	0.000222	0.000908	CcSEcCtD
Dipyridamole—Flushing—Epirubicin—ovarian cancer	0.000222	0.000906	CcSEcCtD
Dipyridamole—Cardiac disorder—Epirubicin—ovarian cancer	0.000222	0.000906	CcSEcCtD
Dipyridamole—Rhinitis—Doxorubicin—ovarian cancer	0.000222	0.000905	CcSEcCtD
Dipyridamole—Dyspepsia—Docetaxel—ovarian cancer	0.000222	0.000905	CcSEcCtD
Dipyridamole—Haemorrhage—Doxorubicin—ovarian cancer	0.000221	0.000903	CcSEcCtD
Dipyridamole—Hepatitis—Doxorubicin—ovarian cancer	0.000221	0.000903	CcSEcCtD
Dipyridamole—Hypoaesthesia—Doxorubicin—ovarian cancer	0.00022	0.000899	CcSEcCtD
Dipyridamole—Pharyngitis—Doxorubicin—ovarian cancer	0.000219	0.000896	CcSEcCtD
Dipyridamole—Hypersensitivity—Paclitaxel—ovarian cancer	0.000219	0.000894	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000217	0.000888	CcSEcCtD
Dipyridamole—Fatigue—Docetaxel—ovarian cancer	0.000217	0.000886	CcSEcCtD
Dipyridamole—Angiopathy—Epirubicin—ovarian cancer	0.000217	0.000886	CcSEcCtD
Dipyridamole—Immune system disorder—Epirubicin—ovarian cancer	0.000216	0.000882	CcSEcCtD
Dipyridamole—Mediastinal disorder—Epirubicin—ovarian cancer	0.000215	0.00088	CcSEcCtD
Dipyridamole—Pain—Docetaxel—ovarian cancer	0.000215	0.000879	CcSEcCtD
Dipyridamole—Chills—Epirubicin—ovarian cancer	0.000214	0.000876	CcSEcCtD
Dipyridamole—Arrhythmia—Epirubicin—ovarian cancer	0.000213	0.000872	CcSEcCtD
Dipyridamole—Asthenia—Paclitaxel—ovarian cancer	0.000213	0.00087	CcSEcCtD
Dipyridamole—Alopecia—Epirubicin—ovarian cancer	0.000211	0.000862	CcSEcCtD
Dipyridamole—Pruritus—Paclitaxel—ovarian cancer	0.00021	0.000858	CcSEcCtD
Dipyridamole—Feeling abnormal—Docetaxel—ovarian cancer	0.000207	0.000847	CcSEcCtD
Dipyridamole—Tinnitus—Doxorubicin—ovarian cancer	0.000206	0.000842	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000206	0.000841	CcSEcCtD
Dipyridamole—Flushing—Doxorubicin—ovarian cancer	0.000205	0.000838	CcSEcCtD
Dipyridamole—Cardiac disorder—Doxorubicin—ovarian cancer	0.000205	0.000838	CcSEcCtD
Dipyridamole—Flatulence—Epirubicin—ovarian cancer	0.000205	0.000837	CcSEcCtD
Dipyridamole—Tension—Epirubicin—ovarian cancer	0.000204	0.000834	CcSEcCtD
Dipyridamole—Dysgeusia—Epirubicin—ovarian cancer	0.000204	0.000832	CcSEcCtD
Dipyridamole—Diarrhoea—Paclitaxel—ovarian cancer	0.000203	0.00083	CcSEcCtD
Dipyridamole—ABCB1—testis—ovarian cancer	0.000202	0.000855	CbGeAlD
Dipyridamole—Nervousness—Epirubicin—ovarian cancer	0.000202	0.000825	CcSEcCtD
Dipyridamole—Back pain—Epirubicin—ovarian cancer	0.000201	0.000822	CcSEcCtD
Dipyridamole—Angiopathy—Doxorubicin—ovarian cancer	0.000201	0.000819	CcSEcCtD
Dipyridamole—Muscle spasms—Epirubicin—ovarian cancer	0.0002	0.000817	CcSEcCtD
Dipyridamole—Immune system disorder—Doxorubicin—ovarian cancer	0.0002	0.000816	CcSEcCtD
Dipyridamole—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000199	0.000814	CcSEcCtD
Dipyridamole—Abdominal pain—Docetaxel—ovarian cancer	0.000199	0.000813	CcSEcCtD
Dipyridamole—Chills—Doxorubicin—ovarian cancer	0.000198	0.00081	CcSEcCtD
Dipyridamole—Arrhythmia—Doxorubicin—ovarian cancer	0.000198	0.000807	CcSEcCtD
Dipyridamole—Dizziness—Paclitaxel—ovarian cancer	0.000196	0.000802	CcSEcCtD
Dipyridamole—Alopecia—Doxorubicin—ovarian cancer	0.000195	0.000798	CcSEcCtD
Dipyridamole—Ill-defined disorder—Epirubicin—ovarian cancer	0.000193	0.000788	CcSEcCtD
Dipyridamole—Anaemia—Epirubicin—ovarian cancer	0.000192	0.000785	CcSEcCtD
Dipyridamole—Flatulence—Doxorubicin—ovarian cancer	0.00019	0.000775	CcSEcCtD
Dipyridamole—Tension—Doxorubicin—ovarian cancer	0.000189	0.000771	CcSEcCtD
Dipyridamole—Vomiting—Paclitaxel—ovarian cancer	0.000189	0.000771	CcSEcCtD
Dipyridamole—Dysgeusia—Doxorubicin—ovarian cancer	0.000189	0.00077	CcSEcCtD
Dipyridamole—Malaise—Epirubicin—ovarian cancer	0.000188	0.000766	CcSEcCtD
Dipyridamole—Rash—Paclitaxel—ovarian cancer	0.000187	0.000765	CcSEcCtD
Dipyridamole—Dermatitis—Paclitaxel—ovarian cancer	0.000187	0.000764	CcSEcCtD
Dipyridamole—Nervousness—Doxorubicin—ovarian cancer	0.000187	0.000764	CcSEcCtD
Dipyridamole—Vertigo—Epirubicin—ovarian cancer	0.000187	0.000763	CcSEcCtD
Dipyridamole—Syncope—Epirubicin—ovarian cancer	0.000187	0.000762	CcSEcCtD
Dipyridamole—Back pain—Doxorubicin—ovarian cancer	0.000186	0.00076	CcSEcCtD
Dipyridamole—Headache—Paclitaxel—ovarian cancer	0.000186	0.00076	CcSEcCtD
Dipyridamole—Hypersensitivity—Docetaxel—ovarian cancer	0.000185	0.000757	CcSEcCtD
Dipyridamole—Muscle spasms—Doxorubicin—ovarian cancer	0.000185	0.000756	CcSEcCtD
Dipyridamole—Palpitations—Epirubicin—ovarian cancer	0.000184	0.000751	CcSEcCtD
Dipyridamole—Loss of consciousness—Epirubicin—ovarian cancer	0.000183	0.000747	CcSEcCtD
Dipyridamole—Cough—Epirubicin—ovarian cancer	0.000182	0.000741	CcSEcCtD
Dipyridamole—Asthenia—Docetaxel—ovarian cancer	0.000181	0.000738	CcSEcCtD
Dipyridamole—Convulsion—Epirubicin—ovarian cancer	0.00018	0.000736	CcSEcCtD
Dipyridamole—Hypertension—Epirubicin—ovarian cancer	0.00018	0.000734	CcSEcCtD
Dipyridamole—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000179	0.000729	CcSEcCtD
Dipyridamole—Pruritus—Docetaxel—ovarian cancer	0.000178	0.000727	CcSEcCtD
Dipyridamole—Anaemia—Doxorubicin—ovarian cancer	0.000178	0.000727	CcSEcCtD
Dipyridamole—Arthralgia—Epirubicin—ovarian cancer	0.000177	0.000723	CcSEcCtD
Dipyridamole—Chest pain—Epirubicin—ovarian cancer	0.000177	0.000723	CcSEcCtD
Dipyridamole—Myalgia—Epirubicin—ovarian cancer	0.000177	0.000723	CcSEcCtD
Dipyridamole—Anxiety—Epirubicin—ovarian cancer	0.000177	0.000721	CcSEcCtD
Dipyridamole—Nausea—Paclitaxel—ovarian cancer	0.000176	0.00072	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000176	0.000718	CcSEcCtD
Dipyridamole—Discomfort—Epirubicin—ovarian cancer	0.000175	0.000715	CcSEcCtD
Dipyridamole—Malaise—Doxorubicin—ovarian cancer	0.000174	0.000709	CcSEcCtD
Dipyridamole—Dry mouth—Epirubicin—ovarian cancer	0.000173	0.000707	CcSEcCtD
Dipyridamole—Vertigo—Doxorubicin—ovarian cancer	0.000173	0.000706	CcSEcCtD
Dipyridamole—Syncope—Doxorubicin—ovarian cancer	0.000173	0.000705	CcSEcCtD
Dipyridamole—Diarrhoea—Docetaxel—ovarian cancer	0.000172	0.000703	CcSEcCtD
Dipyridamole—Palpitations—Doxorubicin—ovarian cancer	0.00017	0.000695	CcSEcCtD
Dipyridamole—Anaphylactic shock—Epirubicin—ovarian cancer	0.00017	0.000693	CcSEcCtD
Dipyridamole—Oedema—Epirubicin—ovarian cancer	0.00017	0.000693	CcSEcCtD
Dipyridamole—Loss of consciousness—Doxorubicin—ovarian cancer	0.000169	0.000691	CcSEcCtD
Dipyridamole—Cough—Doxorubicin—ovarian cancer	0.000168	0.000686	CcSEcCtD
Dipyridamole—Shock—Epirubicin—ovarian cancer	0.000167	0.000682	CcSEcCtD
Dipyridamole—Convulsion—Doxorubicin—ovarian cancer	0.000167	0.000681	CcSEcCtD
Dipyridamole—Nervous system disorder—Epirubicin—ovarian cancer	0.000167	0.00068	CcSEcCtD
Dipyridamole—Dizziness—Docetaxel—ovarian cancer	0.000166	0.00068	CcSEcCtD
Dipyridamole—Thrombocytopenia—Epirubicin—ovarian cancer	0.000166	0.000679	CcSEcCtD
Dipyridamole—Hypertension—Doxorubicin—ovarian cancer	0.000166	0.000679	CcSEcCtD
Dipyridamole—Tachycardia—Epirubicin—ovarian cancer	0.000166	0.000677	CcSEcCtD
Dipyridamole—Skin disorder—Epirubicin—ovarian cancer	0.000165	0.000674	CcSEcCtD
Dipyridamole—Hyperhidrosis—Epirubicin—ovarian cancer	0.000164	0.00067	CcSEcCtD
Dipyridamole—Chest pain—Doxorubicin—ovarian cancer	0.000164	0.000669	CcSEcCtD
Dipyridamole—Arthralgia—Doxorubicin—ovarian cancer	0.000164	0.000669	CcSEcCtD
Dipyridamole—Myalgia—Doxorubicin—ovarian cancer	0.000164	0.000669	CcSEcCtD
Dipyridamole—Anxiety—Doxorubicin—ovarian cancer	0.000163	0.000667	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000163	0.000665	CcSEcCtD
Dipyridamole—Discomfort—Doxorubicin—ovarian cancer	0.000162	0.000661	CcSEcCtD
Dipyridamole—Dry mouth—Doxorubicin—ovarian cancer	0.00016	0.000655	CcSEcCtD
Dipyridamole—Vomiting—Docetaxel—ovarian cancer	0.00016	0.000654	CcSEcCtD
Dipyridamole—Rash—Docetaxel—ovarian cancer	0.000159	0.000648	CcSEcCtD
Dipyridamole—Hypotension—Epirubicin—ovarian cancer	0.000159	0.000648	CcSEcCtD
Dipyridamole—Dermatitis—Docetaxel—ovarian cancer	0.000159	0.000648	CcSEcCtD
Dipyridamole—Headache—Docetaxel—ovarian cancer	0.000158	0.000644	CcSEcCtD
Dipyridamole—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000157	0.000642	CcSEcCtD
Dipyridamole—Oedema—Doxorubicin—ovarian cancer	0.000157	0.000642	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000155	0.000632	CcSEcCtD
Dipyridamole—Shock—Doxorubicin—ovarian cancer	0.000155	0.000631	CcSEcCtD
Dipyridamole—Nervous system disorder—Doxorubicin—ovarian cancer	0.000154	0.000629	CcSEcCtD
Dipyridamole—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000154	0.000628	CcSEcCtD
Dipyridamole—Tachycardia—Doxorubicin—ovarian cancer	0.000153	0.000626	CcSEcCtD
Dipyridamole—Skin disorder—Doxorubicin—ovarian cancer	0.000153	0.000623	CcSEcCtD
Dipyridamole—Paraesthesia—Epirubicin—ovarian cancer	0.000152	0.000623	CcSEcCtD
Dipyridamole—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000152	0.00062	CcSEcCtD
Dipyridamole—Dyspnoea—Epirubicin—ovarian cancer	0.000151	0.000618	CcSEcCtD
Dipyridamole—Somnolence—Epirubicin—ovarian cancer	0.000151	0.000616	CcSEcCtD
Dipyridamole—Nausea—Docetaxel—ovarian cancer	0.00015	0.000611	CcSEcCtD
Dipyridamole—Dyspepsia—Epirubicin—ovarian cancer	0.000149	0.00061	CcSEcCtD
Dipyridamole—Hypotension—Doxorubicin—ovarian cancer	0.000147	0.0006	CcSEcCtD
Dipyridamole—ABCB1—lymph node—ovarian cancer	0.000147	0.000619	CbGeAlD
Dipyridamole—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000147	0.000599	CcSEcCtD
Dipyridamole—Fatigue—Epirubicin—ovarian cancer	0.000146	0.000598	CcSEcCtD
Dipyridamole—Pain—Epirubicin—ovarian cancer	0.000145	0.000593	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000143	0.000585	CcSEcCtD
Dipyridamole—Paraesthesia—Doxorubicin—ovarian cancer	0.000141	0.000576	CcSEcCtD
Dipyridamole—Dyspnoea—Doxorubicin—ovarian cancer	0.00014	0.000572	CcSEcCtD
Dipyridamole—Feeling abnormal—Epirubicin—ovarian cancer	0.00014	0.000571	CcSEcCtD
Dipyridamole—Somnolence—Doxorubicin—ovarian cancer	0.00014	0.00057	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000139	0.000567	CcSEcCtD
Dipyridamole—Dyspepsia—Doxorubicin—ovarian cancer	0.000138	0.000565	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000136	0.000554	CcSEcCtD
Dipyridamole—Fatigue—Doxorubicin—ovarian cancer	0.000135	0.000553	CcSEcCtD
Dipyridamole—Urticaria—Epirubicin—ovarian cancer	0.000135	0.000551	CcSEcCtD
Dipyridamole—Pain—Doxorubicin—ovarian cancer	0.000134	0.000549	CcSEcCtD
Dipyridamole—Abdominal pain—Epirubicin—ovarian cancer	0.000134	0.000548	CcSEcCtD
Dipyridamole—Feeling abnormal—Doxorubicin—ovarian cancer	0.000129	0.000529	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000128	0.000525	CcSEcCtD
Dipyridamole—Hypersensitivity—Epirubicin—ovarian cancer	0.000125	0.000511	CcSEcCtD
Dipyridamole—Urticaria—Doxorubicin—ovarian cancer	0.000125	0.00051	CcSEcCtD
Dipyridamole—Abdominal pain—Doxorubicin—ovarian cancer	0.000124	0.000507	CcSEcCtD
Dipyridamole—Asthenia—Epirubicin—ovarian cancer	0.000122	0.000498	CcSEcCtD
Dipyridamole—Pruritus—Epirubicin—ovarian cancer	0.00012	0.000491	CcSEcCtD
Dipyridamole—Diarrhoea—Epirubicin—ovarian cancer	0.000116	0.000474	CcSEcCtD
Dipyridamole—Hypersensitivity—Doxorubicin—ovarian cancer	0.000116	0.000473	CcSEcCtD
Dipyridamole—Asthenia—Doxorubicin—ovarian cancer	0.000113	0.00046	CcSEcCtD
Dipyridamole—Dizziness—Epirubicin—ovarian cancer	0.000112	0.000459	CcSEcCtD
Dipyridamole—Pruritus—Doxorubicin—ovarian cancer	0.000111	0.000454	CcSEcCtD
Dipyridamole—Vomiting—Epirubicin—ovarian cancer	0.000108	0.000441	CcSEcCtD
Dipyridamole—Diarrhoea—Doxorubicin—ovarian cancer	0.000107	0.000439	CcSEcCtD
Dipyridamole—Rash—Epirubicin—ovarian cancer	0.000107	0.000437	CcSEcCtD
Dipyridamole—Dermatitis—Epirubicin—ovarian cancer	0.000107	0.000437	CcSEcCtD
Dipyridamole—Headache—Epirubicin—ovarian cancer	0.000106	0.000434	CcSEcCtD
Dipyridamole—Dizziness—Doxorubicin—ovarian cancer	0.000104	0.000424	CcSEcCtD
Dipyridamole—Nausea—Epirubicin—ovarian cancer	0.000101	0.000412	CcSEcCtD
Dipyridamole—Vomiting—Doxorubicin—ovarian cancer	9.99e-05	0.000408	CcSEcCtD
Dipyridamole—Rash—Doxorubicin—ovarian cancer	9.91e-05	0.000405	CcSEcCtD
Dipyridamole—Dermatitis—Doxorubicin—ovarian cancer	9.9e-05	0.000404	CcSEcCtD
Dipyridamole—Headache—Doxorubicin—ovarian cancer	9.84e-05	0.000402	CcSEcCtD
Dipyridamole—Nausea—Doxorubicin—ovarian cancer	9.33e-05	0.000381	CcSEcCtD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CB—ovarian cancer	1.66e-05	6.64e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CTNNB1—ovarian cancer	1.65e-05	6.58e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—HRAS—ovarian cancer	1.64e-05	6.56e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CD—ovarian cancer	1.63e-05	6.52e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—PIK3CA—ovarian cancer	1.63e-05	6.51e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—MAPK3—ovarian cancer	1.63e-05	6.5e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—MAPK3—ovarian cancer	1.63e-05	6.49e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—HRAS—ovarian cancer	1.63e-05	6.49e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—HRAS—ovarian cancer	1.63e-05	6.49e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—PIK3CA—ovarian cancer	1.62e-05	6.46e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—PIK3CA—ovarian cancer	1.61e-05	6.42e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTEN—ovarian cancer	1.61e-05	6.42e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—PIK3CA—ovarian cancer	1.61e-05	6.42e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—KRAS—ovarian cancer	1.6e-05	6.39e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CXCL8—ovarian cancer	1.6e-05	6.38e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—HRAS—ovarian cancer	1.59e-05	6.34e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—ERBB2—ovarian cancer	1.58e-05	6.3e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TP53—ovarian cancer	1.58e-05	6.29e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—STAT3—ovarian cancer	1.57e-05	6.28e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—STAT3—ovarian cancer	1.57e-05	6.28e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—NRAS—ovarian cancer	1.57e-05	6.26e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—NRAS—ovarian cancer	1.57e-05	6.26e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—PIK3CA—ovarian cancer	1.57e-05	6.26e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—PIK3CA—ovarian cancer	1.56e-05	6.24e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1B—ovarian cancer	1.56e-05	6.23e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MTOR—ovarian cancer	1.56e-05	6.22e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CB—ovarian cancer	1.56e-05	6.22e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—STAT3—ovarian cancer	1.56e-05	6.22e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—IL6—ovarian cancer	1.56e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—IL6—ovarian cancer	1.56e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—ovarian cancer	1.56e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—NRAS—ovarian cancer	1.55e-05	6.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—MAPK1—ovarian cancer	1.55e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—EGFR—ovarian cancer	1.55e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—MAPK1—ovarian cancer	1.55e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—EGFR—ovarian cancer	1.55e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—AKT1—ovarian cancer	1.55e-05	6.17e-05	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—AKT1—ovarian cancer	1.54e-05	6.16e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—ERBB2—ovarian cancer	1.54e-05	6.13e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.54e-05	6.13e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CASP3—ovarian cancer	1.53e-05	6.11e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL2—ovarian cancer	1.53e-05	6.1e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—IL6—ovarian cancer	1.52e-05	6.07e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—ovarian cancer	1.52e-05	6.05e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CB—ovarian cancer	1.52e-05	6.05e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MTOR—ovarian cancer	1.52e-05	6.05e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—HRAS—ovarian cancer	1.51e-05	6.02e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MAPK3—ovarian cancer	1.5e-05	6e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MAPK3—ovarian cancer	1.5e-05	6e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CXCL8—ovarian cancer	1.5e-05	5.97e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CD—ovarian cancer	1.5e-05	5.97e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCND1—ovarian cancer	1.49e-05	5.94e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—MAPK3—ovarian cancer	1.49e-05	5.94e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—HRAS—ovarian cancer	1.49e-05	5.94e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—HRAS—ovarian cancer	1.49e-05	5.94e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.49e-05	5.93e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—PIK3CA—ovarian cancer	1.48e-05	5.91e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CTNNB1—ovarian cancer	1.48e-05	5.89e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTEN—ovarian cancer	1.47e-05	5.88e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—PIK3CA—ovarian cancer	1.47e-05	5.87e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—KRAS—ovarian cancer	1.46e-05	5.84e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KRAS—ovarian cancer	1.46e-05	5.84e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1B—ovarian cancer	1.46e-05	5.83e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MYC—ovarian cancer	1.46e-05	5.83e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MYC—ovarian cancer	1.46e-05	5.83e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CXCL8—ovarian cancer	1.46e-05	5.81e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—AKT1—ovarian cancer	1.45e-05	5.79e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—HRAS—ovarian cancer	1.45e-05	5.79e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—HRAS—ovarian cancer	1.45e-05	5.77e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MMP9—ovarian cancer	1.45e-05	5.77e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—AKT1—ovarian cancer	1.45e-05	5.77e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ERBB2—ovarian cancer	1.44e-05	5.76e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—IL6—ovarian cancer	1.44e-05	5.76e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—STAT3—ovarian cancer	1.44e-05	5.74e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PTEN—ovarian cancer	1.44e-05	5.74e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—AKT1—ovarian cancer	1.44e-05	5.73e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—AKT1—ovarian cancer	1.44e-05	5.73e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NRAS—ovarian cancer	1.43e-05	5.73e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CASP3—ovarian cancer	1.43e-05	5.72e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL2—ovarian cancer	1.43e-05	5.71e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PIK3CA—ovarian cancer	1.43e-05	5.71e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MAPK1—ovarian cancer	1.43e-05	5.7e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MAPK1—ovarian cancer	1.43e-05	5.7e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—EGFR—ovarian cancer	1.43e-05	5.7e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—EGFR—ovarian cancer	1.43e-05	5.7e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CB—ovarian cancer	1.43e-05	5.69e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MTOR—ovarian cancer	1.43e-05	5.69e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IL6—ovarian cancer	1.42e-05	5.68e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—IL6—ovarian cancer	1.42e-05	5.68e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1B—ovarian cancer	1.42e-05	5.68e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—MAPK1—ovarian cancer	1.42e-05	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—EGFR—ovarian cancer	1.42e-05	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—AKT1—ovarian cancer	1.41e-05	5.61e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—AKT1—ovarian cancer	1.4e-05	5.6e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCND1—ovarian cancer	1.39e-05	5.57e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CASP3—ovarian cancer	1.39e-05	5.56e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL2—ovarian cancer	1.39e-05	5.55e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IL6—ovarian cancer	1.39e-05	5.54e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—YAP1—ovarian cancer	1.39e-05	5.53e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—IL6—ovarian cancer	1.39e-05	5.53e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CTNNB1—ovarian cancer	1.38e-05	5.51e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MAPK3—ovarian cancer	1.37e-05	5.48e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CXCL8—ovarian cancer	1.37e-05	5.46e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—HRAS—ovarian cancer	1.36e-05	5.43e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCND1—ovarian cancer	1.36e-05	5.41e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MMP9—ovarian cancer	1.35e-05	5.4e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KRAS—ovarian cancer	1.35e-05	5.39e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KRAS—ovarian cancer	1.35e-05	5.39e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PTEN—ovarian cancer	1.35e-05	5.37e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—PIK3CA—ovarian cancer	1.35e-05	5.37e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CTNNB1—ovarian cancer	1.34e-05	5.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—PIK3CA—ovarian cancer	1.34e-05	5.36e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KRAS—ovarian cancer	1.34e-05	5.34e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1B—ovarian cancer	1.34e-05	5.34e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MYC—ovarian cancer	1.34e-05	5.33e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—AKT1—ovarian cancer	1.33e-05	5.32e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—AKT1—ovarian cancer	1.32e-05	5.28e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ERBB2—ovarian cancer	1.32e-05	5.27e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MMP9—ovarian cancer	1.32e-05	5.26e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—AKT1—ovarian cancer	1.31e-05	5.24e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—AKT1—ovarian cancer	1.31e-05	5.24e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CASP3—ovarian cancer	1.31e-05	5.23e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PTEN—ovarian cancer	1.31e-05	5.23e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL2—ovarian cancer	1.31e-05	5.22e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MAPK1—ovarian cancer	1.31e-05	5.22e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EGFR—ovarian cancer	1.31e-05	5.22e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CB—ovarian cancer	1.3e-05	5.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MTOR—ovarian cancer	1.3e-05	5.2e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—IL6—ovarian cancer	1.3e-05	5.2e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—VEGFA—ovarian cancer	1.3e-05	5.18e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—STAT3—ovarian cancer	1.29e-05	5.13e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NRAS—ovarian cancer	1.28e-05	5.12e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—AKT1—ovarian cancer	1.28e-05	5.11e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—AKT1—ovarian cancer	1.28e-05	5.1e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCND1—ovarian cancer	1.28e-05	5.09e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CTNNB1—ovarian cancer	1.26e-05	5.04e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.25e-05	5e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CXCL8—ovarian cancer	1.25e-05	5e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—HRAS—ovarian cancer	1.24e-05	4.97e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—HRAS—ovarian cancer	1.24e-05	4.96e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PIK3CA—ovarian cancer	1.24e-05	4.95e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PIK3CA—ovarian cancer	1.24e-05	4.95e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MMP9—ovarian cancer	1.24e-05	4.94e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KRAS—ovarian cancer	1.24e-05	4.93e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PTEN—ovarian cancer	1.23e-05	4.91e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PIK3CA—ovarian cancer	1.23e-05	4.9e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MAPK3—ovarian cancer	1.23e-05	4.9e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1B—ovarian cancer	1.22e-05	4.88e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—VEGFA—ovarian cancer	1.22e-05	4.85e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—AKT1—ovarian cancer	1.21e-05	4.83e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—STAT3—ovarian cancer	1.2e-05	4.8e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—AKT1—ovarian cancer	1.2e-05	4.79e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NRAS—ovarian cancer	1.2e-05	4.79e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CASP3—ovarian cancer	1.2e-05	4.78e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL2—ovarian cancer	1.2e-05	4.78e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MYC—ovarian cancer	1.2e-05	4.77e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—IL6—ovarian cancer	1.19e-05	4.75e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL6—ovarian cancer	1.19e-05	4.75e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—VEGFA—ovarian cancer	1.18e-05	4.72e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—STAT3—ovarian cancer	1.17e-05	4.67e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MAPK1—ovarian cancer	1.17e-05	4.66e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EGFR—ovarian cancer	1.17e-05	4.66e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NRAS—ovarian cancer	1.17e-05	4.66e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—AKT1—ovarian cancer	1.17e-05	4.66e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCND1—ovarian cancer	1.17e-05	4.66e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CTNNB1—ovarian cancer	1.16e-05	4.61e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MAPK3—ovarian cancer	1.15e-05	4.59e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—HRAS—ovarian cancer	1.15e-05	4.58e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—HRAS—ovarian cancer	1.15e-05	4.58e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—HRAS—ovarian cancer	1.14e-05	4.54e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PIK3CA—ovarian cancer	1.13e-05	4.53e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MMP9—ovarian cancer	1.13e-05	4.52e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—FASN—ovarian cancer	1.13e-05	4.51e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PTEN—ovarian cancer	1.13e-05	4.49e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MAPK3—ovarian cancer	1.12e-05	4.47e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MYC—ovarian cancer	1.12e-05	4.46e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—VEGFA—ovarian cancer	1.11e-05	4.44e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.11e-05	4.44e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KRAS—ovarian cancer	1.1e-05	4.41e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—STAT3—ovarian cancer	1.1e-05	4.39e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—AKT1—ovarian cancer	1.1e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NRAS—ovarian cancer	1.1e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IL6—ovarian cancer	1.1e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IL6—ovarian cancer	1.1e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—AKT1—ovarian cancer	1.1e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MAPK1—ovarian cancer	1.09e-05	4.37e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EGFR—ovarian cancer	1.09e-05	4.37e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MYC—ovarian cancer	1.09e-05	4.34e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL6—ovarian cancer	1.09e-05	4.34e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.07e-05	4.29e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MAPK1—ovarian cancer	1.06e-05	4.25e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EGFR—ovarian cancer	1.06e-05	4.25e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MAPK3—ovarian cancer	1.05e-05	4.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HRAS—ovarian cancer	1.05e-05	4.19e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PIK3CA—ovarian cancer	1.04e-05	4.15e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KRAS—ovarian cancer	1.03e-05	4.13e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.03e-05	4.11e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MYC—ovarian cancer	1.02e-05	4.08e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—VEGFA—ovarian cancer	1.02e-05	4.06e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CA—ovarian cancer	1.01e-05	4.05e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—AKT1—ovarian cancer	1.01e-05	4.04e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—AKT1—ovarian cancer	1.01e-05	4.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—STAT3—ovarian cancer	1.01e-05	4.02e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KRAS—ovarian cancer	1.01e-05	4.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NRAS—ovarian cancer	1e-05	4.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IL6—ovarian cancer	1e-05	4.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—AKT1—ovarian cancer	1e-05	4.01e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MAPK1—ovarian cancer	1e-05	3.99e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EGFR—ovarian cancer	1e-05	3.99e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—ovarian cancer	9.81e-06	3.92e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAPK3—ovarian cancer	9.62e-06	3.84e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CA—ovarian cancer	9.5e-06	3.79e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KRAS—ovarian cancer	9.46e-06	3.77e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HRAS—ovarian cancer	9.39e-06	3.75e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MYC—ovarian cancer	9.36e-06	3.73e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—AKT1—ovarian cancer	9.27e-06	3.7e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CA—ovarian cancer	9.24e-06	3.69e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—ovarian cancer	9.19e-06	3.67e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAPK1—ovarian cancer	9.16e-06	3.65e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EGFR—ovarian cancer	9.15e-06	3.65e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPP2R1A—ovarian cancer	9.13e-06	3.64e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL6—ovarian cancer	8.98e-06	3.58e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—ovarian cancer	8.94e-06	3.57e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HRAS—ovarian cancer	8.79e-06	3.51e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CA—ovarian cancer	8.69e-06	3.47e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KRAS—ovarian cancer	8.65e-06	3.45e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HRAS—ovarian cancer	8.55e-06	3.41e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—AKT1—ovarian cancer	8.49e-06	3.39e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL6—ovarian cancer	8.41e-06	3.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—ovarian cancer	8.4e-06	3.35e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TYMS—ovarian cancer	8.33e-06	3.32e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—AKT1—ovarian cancer	8.29e-06	3.31e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL6—ovarian cancer	8.18e-06	3.26e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HRAS—ovarian cancer	8.04e-06	3.21e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CA—ovarian cancer	7.95e-06	3.17e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—AKT1—ovarian cancer	7.76e-06	3.1e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL6—ovarian cancer	7.69e-06	3.07e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—ovarian cancer	7.69e-06	3.07e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—AKT1—ovarian cancer	7.55e-06	3.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HRAS—ovarian cancer	7.35e-06	2.93e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—AKT1—ovarian cancer	7.1e-06	2.83e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL6—ovarian cancer	7.04e-06	2.81e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CAV1—ovarian cancer	6.71e-06	2.68e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AKT1—ovarian cancer	6.49e-06	2.59e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CG—ovarian cancer	6.11e-06	2.44e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CD—ovarian cancer	5.37e-06	2.14e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.68e-06	1.87e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTEN—ovarian cancer	4.05e-06	1.61e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.86e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKT1—ovarian cancer	2.33e-06	9.31e-06	CbGpPWpGaD
